放射性核素氯化锶联合唑来膦酸对骨转移肿瘤止痛疗效的评价

A clinical evaluation of effect of pain palliation of ^(89)SrCl_2 combined with zoledronic acid on cancer patients with bone metastases

目的探讨放射性核素氯化锶(89SrCl2)联合唑来膦酸治疗恶性肿瘤骨转移的止痛疗效。方法 42例恶性肿瘤骨转移患者随机分为单药组和联合组。单药组19例患者采用思通宁(89SrCl2)静脉注射,剂量4mci,每3个月1次;联合组23例患者采用89SrCl2静脉注射,剂量4mci,每3个月1次,用药1个月后,100 ml生理盐水加入唑来膦酸4 mg静脉滴注,每月1次,连续2个月,6个月后评价疗效。结果单药组患者止痛有效率为68.4%,联合组患者为82.6%,,两组差异有统计学意义(P<0.05)。单药组患者消退骨转移病灶疗效有效率为21.1%;联合组患者消退骨转移病灶疗效总有效率为26.1%,两组疗效差异无统计学意义(P>0.05)。结论应用89SrCl2联合唑来膦酸治疗多发性恶性肿瘤骨转移具有良好的止痛效果,值得临床广泛应用。

Objective To study the effect of pain palliation of ^89SrCl2 combined with zoledronic acid on cancer patients with bone metastases. Methods 42 cancer patients with bone metastases were divided into two groups randomly ： group A （ single administration of ^89SrCl2 group, dosage 4mci, once every 3 months, n = 19 ） and group B （ administration of ^89SrCl2 dosage 4mci, once every 3 months, addational administration of zoledronic acid with 100ml NS after one month on the basis of group A, once every one month for consecutive two month, n = 23 ）. Both groups were followed up for 6 months. Results The rates of pain palliation in group A and group B were 68.4 % and 82. 6 % respectively. Effect of pain palliation had significant difference （P 〈0. 05）. The regression of bone metastatic lesions in group A and group B were 21.1% and 26. 1% respectively. No significant difference was observed （P 〉 0. 05 ）. Conclusions Adminstration of ^89SrCl2 combined with zoledronic acid have good effect of pain palliation on cancer patients with bone metastases, which will be a perspective therapy method.